Tumor mechanisms of abiraterone resistance in clinical prostate cancer are not well-defined.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Chen and colleagues report that a T878A androgen receptor mutation occurs in subset of patients progressing while receiving abiraterone, suggesting this may be a therapeutically exploitable mechanism of abiraterone resistance in castration-resistant prostate cancer (CRPC).
Sharifi N. Are you the author?
Cancer Biology, Cleveland Clinic.
Reference: Clin Cancer Res. 2014 Nov 28. pii: clincanres.2899.2014.